Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cytidine is a pyrimidine nucleoside, a fundamental building block of ribonucleic acid (RNA). While Cytidine itself is a naturally occurring molecule, its therapeutic relevance in the provided context primarily stems from its derivative, cytidine monophosphate (CMP). CMP, often administered as part of combination therapies, is being investigated for its neuroprotective and neuroregenerative properties. Clinical trials have explored CMP's potential in treating conditions such as trigeminal neuralgia and neurosensory disturbances following surgical procedures. Additionally, Cytidine is a key component in the metabolism of certain anticancer drugs, as the enzyme cytidine deaminase (CDA) is responsible for metabolizing nucleoside analogs like gemcitabine and decitabine, affecting their bioavailability and efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cytidine.